TribLIVE

| Business

 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Mylan said to raise Meda takeover offer to $6.7B

Email Newsletters

Click here to sign up for one of our email newsletters.

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

'American Coyotes' Series

Traveling by Jeep, boat and foot, Tribune-Review investigative reporter Carl Prine and photojournalist Justin Merriman covered nearly 2,000 miles over two months along the border with Mexico to report on coyotes — the human traffickers who bring illegal immigrants into the United States. Most are Americans working for money and/or drugs. This series reports how their operations have a major impact on life for residents and the environment along the border — and beyond.

Staff and Wire Reports
Friday, April 25, 2014, 2:39 p.m.
 

Mylan Inc., the biggest domestic maker of generic medicines, raised its offer for Swedish drugmaker Meda AB to about $6.7 billion, people with knowledge of the matter said.

The all-stock offer was sent this week, said the people, who asked not to be identified discussing confidential information.

A previous Mylan bid was rejected by Meda, the Swedish company said on April 4, without saying why or disclosing the offer's amount.

Meda would help Cecil-based Mylan expand in generic and branded respiratory and dermatology drugs, and strengthen its position in emerging markets and Europe.

Among Meda's products is the allergy drug Dymista. A majority of Mylan's products are generic versions of branded pharmaceuticals. But it makes EpiPen, a branded drug used to treat severe allergic reactions.

Generic drug manufacturers have been consolidating and buying up new assets as a way to broaden their revenue to include more profitable brand-name drugs and injectable medicines that face less competition.

Mylan has said it is looking to make a “substantial” acquisition this year. The company in December completed a $1.75 billion acquisition of Agila, an Indian maker of injectable medications that doubled the size of Mylan's injectables business.

Nina Devlin, a spokeswoman for Mylan, and Paula Treutiger, a Meda spokeswoman, declined to comment.

Meda's shares were halted in Stockholm trading on Friday. Mylan gained more than 3 percent to close at $52.10.

Actavis Plc, an Irish drugmaker with operations in New Jersey, in February agreed to buy Forest Laboratories Inc. for $25 billion. Valeant Pharmaceuticals International Inc. has been gobbling up drug and health products companies as it seeks to grow into one of the world's five biggest drug manufacturers.

Valeant this week teamed with Bill Ackman, a billionaire hedge fund manager, in a $45.7 billion bid to buy Allergan Inc., the maker of the Botox cosmetic treatment.

Bloomberg News and Trib Total Media staff writer Alex Nixon contributed to this report. Nixon can be reached at 412-320-7928 or anixon@tribweb.com.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Business Headlines

  1. Range Resources cuts workforce 11%
  2. United Airlines hack coincided with incursion into government employee data
  3. Muni bond funds stressed
  4. Post-Gazette offers voluntary buyouts in bid to avoid layoffs
  5. Travelers find direct Web route to Priory’s spirited past in North Side
  6. Voice-assisted technology raises privacy concerns
  7. China rebound, Fed statement fuel rally on Wall Street
  8. Plastics propel Bayer’s 2Q earnings
  9. Fed holds steady on rates
  10. Gold continues to fall further out of favor with investors
  11. Urban rentals pit old vs. young